6
Participants
Start Date
December 31, 2006
Primary Completion Date
October 31, 2008
Study Completion Date
August 31, 2013
CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE
Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
The Methodist Hospital, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Baylor College of Medicine
OTHER